Medtronic Receives the US FDA’s Approval for Micra AV2 and Micra VR2 Leadless Pacing Systems
- The US FDA has granted approval for Medtronic’s next-generation miniaturized, leadless pacemakers i.e., Micra AV2 & Micra VR2x. News pacemakers can provide a battery life of 16yrs. (Micra AV2) & 17yrs. (Micra VR2), respectively
- The devices also offer 40% more battery life & easier programming over previous models in the Micra family of pacemakers, also continue to deliver the benefits of leadless pacing i.e., reduced complications over traditional pacemakers
- Micra AV2 also features advanced algorithms that automatically program AV synchrony helping to coordinate the heart’s upper & lower chambers. Micra AV2 has a higher available tracking capability for faster heart rates (up from 115-135 beats per min. for upper limits)
Ref: PR Newswire | Image: Medtronic
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.